Title : Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.

Pub. Date : 2014 Apr

PMID : 24045439






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Similarly, sunitinib, a small-molecule inhibitor of RET, blocked GDNF-mediated activation of ERK and AKT. Sunitinib ret proto-oncogene Homo sapiens
2 Inhibition of RET either by gene knockdown or by treatment with sunitinib or vandetanib reduced RET-dependent growth of luminal breast cancer cells. Sunitinib ret proto-oncogene Homo sapiens
3 Inhibition of RET either by gene knockdown or by treatment with sunitinib or vandetanib reduced RET-dependent growth of luminal breast cancer cells. Sunitinib ret proto-oncogene Homo sapiens
4 Parallel experiments using treatment with tamoxifen and sunitinib confirmed the increased effectiveness of dual inhibition of the ER and RET pathways in regulating cell growth. Sunitinib ret proto-oncogene Homo sapiens